CrystEngComm · 2012 · 120 citations · 62 references
Natural SciencesChemistryPharmacologyCrystal StructureDrug DiscoveryDrug InteractionsCrystal ChemistryCrystal EngineeringCrystal SystemsCrystallization ProcessesCo-crystal CharacterizationCo-crystal FormationDicarboxylic AcidsEutectic ProcessesPowder Diffraction AnalysisPowder X-ray DiffractionSingle-crystal DiffractionSingle-crystal X-ray Diffraction
Co-crystallization of anti-tubercular drugs pyrazinamide (PZA) and isoniazid (INH) with each other and with dicarboxylic acid coformers was studied. Grinding of the two drugs to make a co-crystal resulted instead in a 1 : 1 binary eutectic, PZA–INH, and addition of succinic acid (SA) and fumaric acid (FA) to the binary drugs gave a 1 : 1 : 1 ternary eutectic composition, PZA–SA–INH and PZA–FA–INH, respectively. The 1 : 0.5 binary drug–diacid adducts, PZA–SA, PZA–FA, INH–SA and INH–FA, are co-crystal structures by single crystal X-ray diffraction. The ternary eutectics PZA–diacid–INH were identified as composed of the co-crystals PZA–(diacid)0.5 and INH–diacid(0.5) rather than the pure components. All new crystalline multi-component phases were characterized by powder X-ray diffraction, differential scanning calorimetry, infrared, and solid-state NMR. Solubility and dissolution experiments on the novel phases showed that their intrinsic dissolution rates are in the order, PZA–SA–INH > INH > PZA–INH > PZA–FA–INH > PZA. Thus pyrazinamide–isoniazid two-drug combination becomes a fast dissolving ternary eutectic phase with succinic acid.
62
Pharmaceutical Cocrystals and Their Physicochemical Properties
N. Schultheiss, Ann Newman · Crystal Growth & Design · 2009 · 1.5K citations · Full text
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
N.J. Babu, Ashwini Nangia · Crystal Growth & Design · 2011 · 986 citations
Pharmacy, Chemistry, Pharmacology +17
Solubility Advantage of Pharmaceutical Cocrystals
David Good, Naír Rodríguez‐Hornedo · Crystal Growth & Design · 2009 · 832 citations